Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre‐ and post‐ponatinib era

American Journal of Hematology(2023)10.1002/ajh.27037Source: DataRank Database

Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre‐ and post‐ponatinib era is a research paper published in American Journal of Hematology (2023). On theSindex it has a DataRank of 0. It has been cited 20 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access20 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)OA: bronzeTopics (8)IDs (PubMed, PMC)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (16)

Koji Sasaki ORCID,Aram Bidikian ORCID,Ghayas C. Issa ORCID,Tapan M. Kadia ORCID,Nitin Jain ORCID

Live enrichment

PubMed:37485584 PMC:PMC11526380

NCI NIH HHS

Grant: P50 CA100632

NCI NIH HHS

Grant: P30 CA016672

National Institutes of Health

bronze

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ajh.27037

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/11526380

MeSH Terms

HumansImidazolesPyridazinesFusion Proteins, bcr-ablProtein Kinase InhibitorsDrug Resistance, NeoplasmMutationLeukemia, Myelogenous, Chronic, BCR-ABL Positive